Deals
Sanofi Said Near Vote to Seal $74-a-Share Genzyme Deal Today
This article is for subscribers only.
Sanofi-Aventis SA may announce an agreement to buy Genzyme Corp. for about $74 a share as soon as today, said four people with knowledge of the matter.
Sanofi also may make potential additional payments tied to the performance of Genzyme’s multiple sclerosis drug, said the people, who declined to be identified because the matter is private. Genzyme’s board was scheduled to vote Feb. 15 on the deal, one person said.